Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloperidol plasma levels and dose optimization

W Coryell1, D D Miller, P J Perry

  • 1Department of Psychiatry, University of Iowa College of Medicine, Iowa City 52242, USA.

The American Journal of Psychiatry
|January 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Antimitotic Agent SP-1-39 Inhibits Head and Neck Squamous Cell Carcinoma.

Journal of dental research·2024
Same author

Mycobacterium immunogenum folliculitis on the lower extremities of a healthy young adult.

Clinical and experimental dermatology·2018
Same author

Journal of Nuclear Cardiology Nuclear Cardiology News Update.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2016
Same author

An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.

Human & experimental toxicology·2015
Same author

Agriculture. Research principles for developing country food value chains.

Science (New York, N.Y.)·2011
Same author

Action of nifedipine in ischemic heart disease.

Canadian family physician Medecin de famille canadien·2011
Same journal

2026 Annual Meeting: President-Elect Address.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: CEO and Medical Director's Address.

The American journal of psychiatry·2026
Same journal

Reports to the Membership.

The American journal of psychiatry·2026
Same journal

Convergent Metabolic Dysregulations But Divergent Contributing Pathways Across Severe Mental Disorders: The Power of Combining Genetics and Metabolomics.

The American journal of psychiatry·2026
Same journal

2026 Annual Meeting: Presidential Address.

The American journal of psychiatry·2026
Same journal

Represcribing Previously Used Antipsychotics: Response to So.

The American journal of psychiatry·2026
See all related articles

For schizophrenia patients with poor response to haloperidol, maintaining plasma levels below 18 ng/ml is more effective. Increasing haloperidol doses beyond this level may be countertherapeutic and not improve outcomes.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Neuroscience

Background:

  • Schizophrenia management often involves optimizing antipsychotic dosing.
  • Haloperidol is a widely used antipsychotic, but its efficacy can vary.
  • Determining optimal plasma levels is crucial for treatment success.

Purpose of the Study:

  • To evaluate the clinical utility of haloperidol plasma level monitoring.
  • To assess the impact of different haloperidol plasma concentrations on treatment response in schizophrenia.
  • To identify optimal therapeutic ranges for haloperidol in non-responsive patients.

Main Methods:

  • A randomized controlled trial involving 66 inpatients with acute schizophrenia.
  • Patients were assigned to fixed haloperidol doses targeting plasma levels of 8-18 ng/ml or 25-35 ng/ml.

Related Experiment Videos

  • Dose reassignment was performed for patients not achieving a 30% improvement in BPRS scores after 3 weeks.

    • Main Results:

    • Survival analysis showed significantly better improvement in patients with haloperidol plasma levels below 18 ng/ml compared to those above 25 ng/ml.
    • No significant differences in side effect ratings were observed between groups.
    • Patients whose doses were reduced from higher levels showed greater improvement than those whose doses were increased.

    Conclusions:

    • Haloperidol plasma levels exceeding 18 ng/ml may be countertherapeutic for schizophrenia.
    • Increasing haloperidol dosage beyond 18 ng/ml is not effective for patients with initial poor response.
    • Plasma level monitoring can guide dose adjustments for improved treatment outcomes.